Pathways to Success Project (PSP) is an Innovation grant focusing on improving vocational rehabilitation outcomes for individuals with disabilities through sector-specific specialist teams in high-demand career pathways. PSP's unique service delivery design and collaboration with San Diego State Uni

4 views • 6 slides

The DRIVE-SHIFT study evaluated switching to DOR/3TC/TDF in HIV patients with suppressed viral loads. The study aimed to assess the efficacy of DOR/3TC/TDF compared to continuation of current antiretroviral therapy (cART) at both 24 and 48 weeks. Results showed non-inferiority of DOR/3TC/TDF in main

1 views • 7 slides

HPTN 069/ACTG A5305 is a Phase II study evaluating the safety and tolerability of Maraviroc (MVC)-containing regimens compared to Tenofovir/emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP) in at-risk women. The study involves a randomized, double-blind, placebo-controlled design with

0 views • 18 slides

ESA provides updates on current activities including GAIA, BepiColombo, Solar Orbiter, JUICE, PN DOR Correlator software testing, Lunar Flashlight validation, and TTCP upgrades. The DDOR status at ESA for Spring 2023 involves operational supports in 4Q2023. Additionally, insights on ESA-JAXA cross-s

0 views • 10 slides

The Nebraska Department of Revenue offers a secure electronic method for taxpayers to upload documents using the State of Nebraska File Sharing system. Follow the provided instructions to successfully upload your documents to the DOR, receive email confirmation, and ensure a smooth process. For any

0 views • 9 slides

Subgroup analysis from the iPrEx trial and open-label extension assessed the efficacy, drug concentrations, and adherence of TDF-FTC PrEP for transgender women assigned male at birth. Results indicate varying drug detection consistency and non-condom receptive anal intercourse among participants.

1 views • 7 slides

DRIVE-FORWARD Study compared the efficacy of doravirine (DOR) with darunavir/ritonavir (DRV/r) in treatment-naive HIV patients. The study aimed to show non-inferiority of DOR based on virologic response at week 48. Results indicated similar virologic response rates between DOR and DRV/r groups, with

0 views • 10 slides

Explore the evolution of school choice in Massachusetts, with over 28 years of history and significant growth in enrollment and tuition rates. Discover important milestones throughout the year for school committees, DOR-DLS, DESE, and LEAs. Learn about the process, forms, and regulations related to

0 views • 21 slides

STAR Study compared the efficacy and safety of RPV/FTC/TDF and EFV/FTC/TDF in treatment-naive HIV patients. The study included 394 participants in each group, assessing HIV RNA suppression rates, CD4 count improvements, treatment responses, and resistance analyses up to 48 weeks. Results showed RPV/

0 views • 15 slides

Department of Rehabilitation (DOR) conducts an annual Consumer Satisfaction Survey in collaboration with the State Rehabilitation Council to assess consumer satisfaction with its services. Recent survey modifications aimed to enhance data accuracy and reduce cognitive load for consumers. With over 5

0 views • 34 slides

In the STARTMRK study, Raltegravir (RAL) was compared to Efavirenz (EFV) in combination with TDF/FTC for the treatment of HIV. The study aimed to demonstrate non-inferiority of RAL compared to EFV in achieving HIV RNA levels below 50 c/mL. Baseline characteristics and patient disposition were assess

0 views • 12 slides

Dolutegravir (DTG) treatment has shown associations with weight gain and clinical obesity, particularly in black individuals and women. In contrast, tenofovir disoproxil fumarate (TDF) is linked to lower body weight compared to other treatments. Trials like ADVANCE and NAMSAL have provided insights

0 views • 31 slides

Study M02-418 compared once-daily (QD) and twice-daily (BID) LPV/r in combination with TDF and FTC for HIV treatment. The primary endpoint was achieving HIV RNA <50 c/mL at week 48, aiming for non-inferiority of QD vs. BID dosing. Patient characteristics, treatment response at week 48, and pharmacok

0 views • 7 slides

The comparison study explores NNRTI regimens alongside the DRIVE-AHEAD trial, focusing on DOR/3TC/TDF vs EFV-FTC/TDF. DRIVE-AHEAD assesses the efficacy and safety of DOR in ARV-naïve HIV patients, aiming for non-inferiority based on virologic response, with DOR exhibiting potential neuropsychiatric

0 views • 11 slides

In this detailed piece, Subhash Khot, Dor Minzer, Dana Moshkovitz, and Muli Safra explore the fascinating concept of Small Set Expansion in Johnson Graphs. The Johnson Graph is defined as a representation where nodes are sets of size K in a universe of size N, and two sets are connected if they inte

0 views • 14 slides

Study results reveal that F/TAF provides rapid onset and longer sustained HIV protection compared to F/TDF in pre-exposure prophylaxis. The randomized noninferiority trial included 2694 participants with a primary analysis at weeks 48 and 96. Disclosure statements indicate involvement of various hea

0 views • 21 slides

Pooled data from 11 F/TDF demonstration projects involving over 6000 cisgender women over eight years examined adherence and HIV incidence. The study aimed to assess the effectiveness of F/TDF for HIV prevention in real-world settings, revealing adherence patterns in a subset of participants. This r

0 views • 16 slides

Achievements from the meeting cycle include progress with higher resolution PN DOR signals, resolution of RIDs, and completion of the final draft of the architecture Magenta Book. Updates to OPS MB-3 and RDEF BB-2 were discussed, along with results from new interoperability tests. Future considerati

0 views • 16 slides

The Washington State Working Families Tax Credit Outreach Advisory Committee met on February 8, 2023, to discuss program updates, application numbers, activities supporting the program, and future steps. They also approved a charter draft and encouraged involvement in promoting the WFTC. Members sha

0 views • 9 slides

Department of Rehabilitation's latest updates include changes to its name, seeking feedback for a new name, staffing details, TBI State Partnership Program grants, and TBI Providers information. The TBI Subcommittee is enhancing services for survivors and caregivers to promote partnerships and infor

0 views • 17 slides

This study aims to describe real-world use patterns and HIV seroconversion rates for individuals using emtricitabine/tenofovir disoproxil fumarate (F/TDF) vs. emtricitabine/tenofovir alafenamide (F/TAF) as pre-exposure prophylaxis (PrEP) for HIV prevention. The retrospective analysis includes newly

0 views • 9 slides

The ATLAS-M Study focused on switching to ATV/r + 3TC in participants with specific criteria, aiming to assess non-inferiority compared to ATV/r + 2 NRTIs. Results at W48 indicated a higher proportion free of treatment failure with ATV/r + 3TC, with notable differences in virologic failure rates and

0 views • 7 slides

Comparison of DTI protocols and measures in 317 participants revealed strong associations with age and cognitive impairment. MD and TDF-FA emerged as best measures, with robust connections to age. NODDI in advanced MRI allows for differentiation of A-beta positive and negative groups, offering great

0 views • 6 slides

This study compares the efficacy and safety of different protease inhibitors (PIs) including ATV, ATV/r, LPV/r, FPV/r, DRV/r, and SQV/r in HIV treatment. The ARTEMIS study specifically focuses on comparing DRV/r and LPV/r in combination with TDF/FTC in ARV-naive patients. Results show non-inferiorit

0 views • 12 slides

Nondumiso, a patient on TDF/FTC/EFV for a year, faces challenges with adherence despite good health and stability. With a VL of 1500, a thorough assessment is needed to address possible causes such as adherence, infections, dosing, interactions, and resistance. Follow-up testing, interventions, and

0 views • 23 slides

The ASPIRE study evaluated the efficacy of switching to DTG + 3TC in HIV patients with stable triple ART regimens. The primary endpoint was treatment failure proportion at W24, with non-inferiority demonstrated at W48. Virologic outcomes, adverse events, and patient dispositions were reported, with

0 views • 4 slides